Editorial: Stem-Cell Reality Check
By admin,
Wall Street Journal
| 12. 27. 2004
California voters approved a stem-cell initiative known as Proposition 71 on November 2. But only recently has anyone gotten around to analyzing the fine print.
The law, which passed with 59% of the vote and vocal support from Republican Governor Arnold Schwarzenegger, authorizes $3 billion in bonds to pay for new research and facilities. And even though the interest rate will double the ultimate cost over 10 years, backers of the initiative said that the money raised from the bonds won_t cost the state anything for the first five.
Or so most Californians thought before a recent report in the San Francisco Chronicle noting that the Prop. 71 campaign misrepresented the measure in major ways. In fact, says the paper, _Interest payments will begin immediately, paid out of the bond money itself_meaning that tens to hundreds of millions of _research_ dollars must be used to pay debt service._
see moreMoreover, the law says the research money doesn_t even have to be spent on embryonic stem-cell studies. It can go to _other scientific and medical research and technologies_ to be determined by...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...